Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB BIOSCIENCES GmbH
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient has advanced idiopathic Parkinson's Disease associated chronic pain assessed by a Likert Pain Scale
Patient is taking Levodopa with a stable daily dose of at least 200 mg for at least 21 days prior to start
Hoehn and Yahr stage score of II to IV
Mini-Mental State Examination (MMSE) score ≥ 25
If an antidepressant drug is taken, the dose must be stable for at least 21 days
You may not be if
Therapy with a Dopamine Agonist within 21 days prior to start
Discontinuation from previous Dopamine Agonist Therapy due to lack of efficacy
Therapy with Dopamine-modulating substances 21 days prior to start
Therapy with analgesics for the treatment for pain, unless the dose has been stable
Chronic alcohol or drug abuse
Medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the patient's ability to participate in this study
Hypersensitivity to any components of the Investigational Medicinal Product (IMP) or comparative drugs
Atypical Parkinson's Disease Syndrome due to drugs
History of deep brain stimulation
Significant skin disease that would make transdermal drug use inappropriate
Electroconvulsive therapy within 12 weeks prior to start
Evidence of an Impulse Control Disorder
Previous diagnosis of severe Restless Legs Syndrome